Andour L, Hagenaars S, Gregus B, Tokes A, Karancsi Z, Tollenaar R
Virchows Arch. 2025; .
PMID: 39904885
DOI: 10.1007/s00428-025-04039-z.
Schlam I, Loi S, Salgado R, Swain S
ESMO Open. 2025; 10(2):104120.
PMID: 39826475
PMC: 11786075.
DOI: 10.1016/j.esmoop.2024.104120.
Nandi D, Sharma D
Front Immunol. 2024; 15:1477980.
PMID: 39555066
PMC: 11563812.
DOI: 10.3389/fimmu.2024.1477980.
Pedrosa R, Kros J, Schrijver B, Berrevoets C, Marques R, van Eijck C
Heliyon. 2024; 10(16):e36598.
PMID: 39262976
PMC: 11388388.
DOI: 10.1016/j.heliyon.2024.e36598.
Jama M, Tabana Y, Barakat K
Eur J Med Res. 2024; 29(1):353.
PMID: 38956700
PMC: 11218087.
DOI: 10.1186/s40001-024-01901-9.
Enhancing AI Research for Breast Cancer: A Comprehensive Review of Tumor-Infiltrating Lymphocyte Datasets.
Fiorin A, Lopez Pablo C, Lejeune M, Hamza Siraj A, Della Mea V
J Imaging Inform Med. 2024; 37(6):2996-3008.
PMID: 38806950
PMC: 11612116.
DOI: 10.1007/s10278-024-01043-8.
Exploring histological predictive biomarkers for immune checkpoint inhibitor therapy response in non-small cell lung cancer.
Cho U, Im S, Park H
J Pathol Transl Med. 2024; 58(2):49-58.
PMID: 38389279
PMC: 10948248.
DOI: 10.4132/jptm.2024.01.31.
Distinct profiles of proliferating CD8+/TCF1+ T cells and CD163+/PD-L1+ macrophages predict risk of relapse differently among treatment-naïve breast cancer subtypes.
Ntostoglou K, Theodorou S, Proctor T, Nikas I, Awounvo S, Sepsa A
Cancer Immunol Immunother. 2024; 73(3):46.
PMID: 38349444
PMC: 10864422.
DOI: 10.1007/s00262-024-03630-8.
Evaluation of immune density, PD-L1, and CXCR4 expressions in metaplastic breast carcinoma to predict potential immunotherapy benefit.
Bagbudar S, Karanlik H, Cabioglu N, Bayram A, Tukenmez M, Aydiner A
Med Oncol. 2023; 41(1):18.
PMID: 38102446
DOI: 10.1007/s12032-023-02243-y.
Initial interactions with the FDA on developing a validation dataset as a medical device development tool.
Hart S, Garcia V, Dudgeon S, Hanna M, Li X, Blenman K
J Pathol. 2023; 261(4):378-384.
PMID: 37794720
PMC: 10841854.
DOI: 10.1002/path.6208.
Multiomics technologies for comprehensive tumor microenvironment analysis in triple-negative breast cancer under neoadjuvant chemotherapy.
Wang G, Yao Y, Huang H, Zhou J, Ni C
Front Oncol. 2023; 13:1131259.
PMID: 37284197
PMC: 10239824.
DOI: 10.3389/fonc.2023.1131259.
Bibliometric analysis of worldwide research trends on breast cancer about inflammation.
Meng G, Xu H, Yang S, Chen F, Wang W, Hu F
Front Oncol. 2023; 13:1166690.
PMID: 37152044
PMC: 10154678.
DOI: 10.3389/fonc.2023.1166690.
Characterization of 5-inflammatory-gene signature to affect the immune status and predict prognosis in breast cancer.
Zang H, Ni G, Gong L
Cent Eur J Immunol. 2023; 47(3):218-233.
PMID: 36817270
PMC: 9896988.
DOI: 10.5114/ceji.2022.121046.
Comparison of the prognostic value of stromal tumor-infiltrating lymphocytes and CD3 + T cells between schistosomal and non-schistosomal colorectal cancer.
Wang W, Zhang Y, Liu J, Jing H, Lu K, Wang L
World J Surg Oncol. 2023; 21(1):31.
PMID: 36726115
PMC: 9890788.
DOI: 10.1186/s12957-023-02911-3.
CCDC69 is a prognostic marker of breast cancer and correlates with tumor immune cell infiltration.
Yi Y, Xu T, Tan Y, Lv W, Zhao C, Wu M
Front Surg. 2022; 9:879921.
PMID: 35910470
PMC: 9334777.
DOI: 10.3389/fsurg.2022.879921.
Enhancement of antitumor immune response by radiation therapy combined with dual immune checkpoint inhibitor in a metastatic model of HER2-positive murine tumor.
Misaki S, Murata S, Shimoji M, Iwai T, Sihombing A, Aoki K
Jpn J Radiol. 2022; 40(12):1307-1315.
PMID: 35763240
PMC: 9719888.
DOI: 10.1007/s11604-022-01303-z.
Epigenetic Repression of STING by MYC Promotes Immune Evasion and Resistance to Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer.
Lee K, Lin C, Servetto A, Bae J, Kandagatla V, Ye D
Cancer Immunol Res. 2022; 10(7):829-843.
PMID: 35561311
PMC: 9250627.
DOI: 10.1158/2326-6066.CIR-21-0826.
Tumor Infiltrating Lymphocytes are Prognostic Factors and Can Be Markers of Sensitivity to Chemoradiotherapy in Head and Neck Squamous Cell Carcinoma.
Suzuki H, Kawasaki Y, Miura M, Hatakeyama H, Shina K, Suzuki S
Asian Pac J Cancer Prev. 2022; 23(4):1271-1278.
PMID: 35485685
PMC: 9375628.
DOI: 10.31557/APJCP.2022.23.4.1271.
Higher CD1a Levels Correlate with PD-L1 Expression and Predict Worse Overall Survival in Triple-Negative Breast Carcinoma.
Zheng J, Wei Y, Li X, Shen Z, Zhang Y, Huang B
Breast Care (Basel). 2022; 17(1):31-39.
PMID: 35355703
PMC: 8914187.
DOI: 10.1159/000513502.
Nanomedicine as a Promising Tool to Overcome Immune Escape in Breast Cancer.
Navarro-Ocon A, Blaya-Canovas J, Lopez-Tejada A, Blancas I, Sanchez-Martin R, Garrido M
Pharmaceutics. 2022; 14(3).
PMID: 35335881
PMC: 8950730.
DOI: 10.3390/pharmaceutics14030505.